tiprankstipranks
Blurbs

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Teva Pharmaceutical (TEVA), HUTCHMED (HCM) and Arcutis Biotherapeutics (ARQT)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Teva Pharmaceutical (TEVAResearch Report), HUTCHMED (HCMResearch Report) and Arcutis Biotherapeutics (ARQTResearch Report).

Teva Pharmaceutical (TEVA)

In a report released today, Nathan Rich from Goldman Sachs maintained a Hold rating on Teva Pharmaceutical, with a price target of $10.00. The company’s shares closed last Monday at $9.48.

According to TipRanks.com, Rich is a 3-star analyst with an average return of 4.6% and a 53.4% success rate. Rich covers the Healthcare sector, focusing on stocks such as Alignment Healthcare, Bright Health Group, and Endo International.

Teva Pharmaceutical has an analyst consensus of Hold, with a price target consensus of $9.60, which is a 4.2% upside from current levels. In a report issued on July 27, J.P. Morgan also maintained a Hold rating on the stock with a $11.00 price target.

See today’s best-performing stocks on TipRanks >>

HUTCHMED (HCM)

In a report released today, Paul Choi from Goldman Sachs maintained a Hold rating on HUTCHMED, with a price target of $14.00. The company’s shares closed last Monday at $12.07, close to its 52-week low of $8.41.

According to TipRanks.com, Choi is a 4-star analyst with an average return of 6.9% and a 50.4% success rate. Choi covers the Healthcare sector, focusing on stocks such as Springworks Therapeutics, BridgeBio Pharma, and FibroGen.

Currently, the analyst consensus on HUTCHMED is a Moderate Buy with an average price target of $18.67.

Arcutis Biotherapeutics (ARQT)

In a report released today, Chris Shibutani from Goldman Sachs maintained a Buy rating on Arcutis Biotherapeutics, with a price target of $50.00. The company’s shares closed last Monday at $20.26.

According to TipRanks.com, Shibutani is a 5-star analyst with an average return of 22.9% and a 47.6% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Amylyx Pharmaceuticals Inc, Prometheus Biosciences, and BioNTech SE.

Arcutis Biotherapeutics has an analyst consensus of Strong Buy, with a price target consensus of $50.40, which is a 103.2% upside from current levels. In a report released today, Morgan Stanley also maintained a Buy rating on the stock with a $45.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on TEVA:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles